Core Insights - Inspira Technologies has begun to see positive impacts from the adoption of its FDA-cleared ART100 system, marking a significant milestone in its commercialization efforts [1][4] - The ART100 system has been successfully integrated into clinical workflows at leading tier-one U.S. hospitals, indicating growing confidence in its capabilities [2][4] - There is increasing interest from additional U.S. and international healthcare institutions and governmental authorities regarding the ART100, prompting the company to scale up operational capabilities [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and breathing spontaneously [5] - Inspira is advancing its proprietary blood sensor platform, HYLA™, which offers continuous, non-invasive monitoring, positioning the company as an attractive player in the life-support and MedTech landscape [5]